Last reviewed · How we verify
mometasone furoate and formoterol
Mometasone furoate is a corticosteroid that reduces airway inflammation, while formoterol is a long-acting beta-2 agonist that relaxes airway smooth muscle, together providing anti-inflammatory and bronchodilator effects.
Mometasone furoate is a corticosteroid that reduces airway inflammation, while formoterol is a long-acting beta-2 agonist that relaxes airway smooth muscle, together providing anti-inflammatory and bronchodilator effects. Used for Asthma maintenance treatment, Chronic obstructive pulmonary disease (COPD) maintenance treatment.
At a glance
| Generic name | mometasone furoate and formoterol |
|---|---|
| Also known as | Dulera |
| Sponsor | Sanofi |
| Drug class | Inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination |
| Target | Glucocorticoid receptor (mometasone); beta-2 adrenergic receptor (formoterol) |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Mometasone furoate binds to glucocorticoid receptors in the lung, suppressing inflammatory cytokine production and reducing airway edema and mucus secretion. Formoterol activates beta-2 adrenergic receptors on airway smooth muscle, causing bronchodilation and improving airflow. The combination provides both rapid and sustained symptom relief in obstructive airway diseases.
Approved indications
- Asthma maintenance treatment
- Chronic obstructive pulmonary disease (COPD) maintenance treatment
Common side effects
- Tremor
- Headache
- Palpitations
- Oral candidiasis
- Nervousness/anxiety
- Muscle cramps
Key clinical trials
- Individualizing Treatment for Asthma in Primary Care (Full Study) (PHASE4)
- Vibroacoustic Therapy With Oscillating Positive Expiratory Pressure in the Treatment of Nasal Congestion (NA)
- Asthma Research in Children and Adolescents
- Individualizing Treatment for Asthma in Primary Care (PHASE4)
- Allergic Rhinitis With/Without Asthma: Pre- and Post-Qipian Analysis
- Study of Mometasone Furoate/Formoterol Fumarate (MF/F) Metered Dose Inhaler (MDI) in Adolescents & Adults With Persistent Asthma (P08212) (PHASE3)
- A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241) (PHASE4)
- A Study of the Bronchodilator Effect of Formoterol Fumarate Used in Combination With Mometasone Furoate Metered Dose Inhaler in Children With Persistent Asthma (P06476 AM2) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- mometasone furoate and formoterol CI brief — competitive landscape report
- mometasone furoate and formoterol updates RSS · CI watch RSS
- Sanofi portfolio CI